Home  »  Trending   »  The Chart for Celldex Therapeutics Inc. (CLDX) Is ...

The Chart for Celldex Therapeutics Inc. (CLDX) Is Flashing Mixed Signals

Celldex Therapeutics Inc. (NASDAQ:CLDX) went up by 10.82% from its latest closing price compared to the recent 1-year high of $57.20. The company’s stock price has collected 10.12% of gains in the last five trading sessions.

Is It Worth Investing in Celldex Therapeutics Inc. (NASDAQ :CLDX) Right Now?

Plus, the 36-month beta value for CLDX is at 2.49. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for Celldex Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $67.00, which is $32.4 above the current price. CLDX currently public float of 46.66M and currently shorts hold a 8.17% ratio of that float. Today, the average trading volume of CLDX was 849.09K shares.

CLDX’s Market Performance

CLDX stocks went up by 10.12% for the week, with a monthly jump of 43.39% and a quarterly performance of 7.07%, while its annual performance rate touched -23.28%. The volatility ratio for the week stands at 6.72% while the volatility levels for the past 30 days are set at 7.09% for Celldex Therapeutics Inc. The simple moving average for the period of the last 20 days is 18.15% for CLDX stocks with a simple moving average of 3.46% for the last 200 days.

Analysts’ Opinion of CLDX

Many brokerage firms have already submitted their reports for CLDX stocks, with Jefferies repeating the rating for CLDX by listing it as a “Buy.” The predicted price for CLDX in the upcoming period, according to Jefferies is $66 based on the research report published on September 17th of the previous year 2021.

SVB Leerink, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $68. The rating they have provided for CLDX stocks is “Outperform” according to the report published on September 10th, 2021.

Guggenheim gave a rating of “Buy” to CLDX, setting the target price at $66 in the report published on July 22nd of the previous year.

CLDX Trading at 29.62% from the 50-Day Moving Average

After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.86% of loss for the given period.

Volatility was left at 7.09%, however, over the last 30 days, the volatility rate increased by 6.72%, as shares surge +32.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.14% upper at present.

During the last 5 trading sessions, CLDX rose by +10.12%, which changed the moving average for the period of 200-days by -24.03% in comparison to the 20-day moving average, which settled at $29.54. In addition, Celldex Therapeutics Inc. saw -10.97% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CLDX starting from Martin Samuel Bates, who sale 9,500 shares at the price of $42.00 back on Dec 23. After this action, Martin Samuel Bates now owns 24,378 shares of Celldex Therapeutics Inc., valued at $399,000 using the latest closing price.

Heath-Chiozzi Margo, the SVP of Regulatory Affairs of Celldex Therapeutics Inc., sale 600 shares at $40.00 during a trade that took place back on Dec 08, which means that Heath-Chiozzi Margo is holding 11,247 shares at $24,000 based on the most recent closing price.

Stock Fundamentals for CLDX

Current profitability levels for the company are sitting at:

  • -1486.73 for the present operating margin
  • +34.04 for the gross margin

The net margin for Celldex Therapeutics Inc. stands at -1516.04. Equity return is now at value -21.40, with -20.10 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 24.86.